PHILADELPHIA (June 2, 2023)—Fox Chase Cancer Center and Temple Health researchers will participate in the presentation and discussion of 10 research projects at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 2-6 in Chicago. An asterisk (*) indicates that the author is the main presenter.
Saturday, June 3
Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles. Anumita Chakraborty*, Jill Hasler, Elizabeth Handorf, Fern Anari, Pooja Ghatalia, Benjamin Miron, Elizabeth Plimack, Daniel Geynisman, Matthew Zibelman; Temple University Health System, Fox Chase Cancer Center, Temple University Health System, Fox Chase Cancer Center, Fox Chase Cancer Center, Temple Health; Session Type: Poster Session; Session Title: Genitourinary Cancer—Kidney and Bladder, Urothelial Cancer – Local-Regional Disease; Abstract #4586, Poster Board #78, Hall A, June 3, 2023, 8:00 AM CDT.
TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC). Hossein Borghaei*, Saiama Waqar, Debora Bruno, Satoru Kitazono, Kazushige Wakuda, Alexander Spira, Jairo Olivares, Gabriel Mak, Susan Lovick, Louise Goodwin, Kyriakos Papadopoulos; Fox Chase Cancer Center, Washington University School of Medicine, University Hospitals, Case Comprehensive Cancer Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Shizuoka Cancer Center Hospital, Virginia Cancer Specialists, Mary Crowley Cancer Research, AstraZeneca, START San Antonio; Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology, Chemotherapy and Antibody-Drug Conjugates; Clinical Trial Registration Number, NCT04612751, Abstract #TPS3158, Poster Board #353b, Hall A, June 3, 2023, 8:00 AM CDT.
Clinical implications of molecular alterations in intraductal carcinoma of the prostate. Benjamin Miron*, Shuanzeng Wei, Yasmine Baca, Daniel Herchenhorn, Isabela Cunha, Kevin Zarrabi, Jacqueline Brown, Matthew Oberley, Chadi Nabhan, Emmanuel Antonarakis, Daniel Geynisman, Rana McKay; Fox Chase Cancer Center, Department of Pathology, Fox Chase Cancer Center, Caris Life Sciences, Oncologia D’Or, A.C. Camargo Cancer Center, Thomas Jefferson University, Winship Cancer Institute of Emory University, University of Minnesota Masonic Cancer Center, University of California San Diego; Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile; Abstract #5024, Poster Board #118, Hall A, June 3, 8:00 AM CDT.
Modeling genetic testing (GT) attitudes in a socio-demographically diverse cohort of patients (pts) with cancer: The importance of race/ethnicity and medical mistrust (MM). Michael Hall*, Karen Ruth, Yana Chertock, Katie Singley, Caseem Luck, Cindy Park, Agostina Waisfeld, Malak Abuhillo, Aleeha Khan, Shreya Gowda, Erin Holland, Elizabeth Knight, Shreya Verma, Alexandru-Mircea Rotaru, Abeeda Hussain-Kasim, Sarah Bass; Fox Chase Cancer Center, Biostatistics and Bioinformatics Core, Fox Chase Cancer Center, Department of Clinical Genetics, Fox Chase Cancer Center, Temple University College of Public Health, Temple University, Lewis Katz School of Medicine; Poster Session: Prevention, Risk Reduction, and Hereditary Cancer, Germline Genetic Testing; Abstract #10562, Poster Board #195, June 3, 2023, Hall A, 1:15 PM CDT.
Training oncologists (Oncs) to conduct better informed discussions with African American (AA) cancer (CA) patients (pts) about tumor genomic profiling (TGP): Results of a randomized pilot trial of Gene Pilot Pro (GPP). Michael Hall,* Ariel Hoadley, Yana Chertock, Patrick Kelly, Katie Singley, Caseem Luck, Sarah Bass; Fox Chase Cancer Center, Temple University College of Public Health, Department of Clinical Genetics, Fox Chase Cancer Center; Poster Session: Prevention, Risk Reduction, and Hereditary Cancer, Germline Genetic Testing; Abstract #10552, Poster Board #185, Hall A, June 3, 2023, 1:15 PM CDT.
Sunday, June 4
Ten-year mastectomy trends among breast cancer phenotypes: A national cohort study. Matthew Lewis Pierotti, MD*, Christian Cruz Pico, Jill Hasler, Austin Williams, Elizabeth Handorf, Allison Aggon, Mary Pronovost, Andrea Porpiglia, Mahtab Vasigh, Richard Bleicher; Fox Chase Cancer Center, Temple University Health System; Breast Cancer—Local/Regional/Adjuvant; Primary Track: Breast Cancer;, Abstract #584, Poster Board #414, Hall A, June 4, 8:00 AM CDT.
Hematology and oncology fellow education about sexual and reproductive health: A survey of program directors in the United States. Jennifer Reese,* Jessica Bauman, Kristen Sorice, Danny Middleton, Sarah McIlhenny, Sharon Bober; Fox Chase Cancer Center, Fox Chase Cancer Center, Temple University Health System, Dana-Farber Cancer Institute/Mass General Brigham; Poster Session: Professional Development and Education Advances, Education Research; Abstract #11029, Poster Board #482, Hall A, June 4, 2023, 8:00 AM CDT.
Addressing resiliency and burnout: A quantitative needs assessment of oncology physician assistants (PAs), Eric Tetzlaff,* Heather Hylton, Karen Ruth, Zachary Hasse, Michael Hall; Fox Chase Cancer Center, Private, Biostatistics and Bioinformatics Core, Fox Chase Cancer Center; Poster Session: Professional Development and Education Advances, Clinician Burnout and Resiliency; Abstract #11016, Poster Board #469, Hall A, June 4, 2023, 8:00 AM CDT.
Monday, June 5
AB-101, an allogeneic, non-genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma. Rashmi Khanal*, Amitkumar Mehta, Joseph Maly, Houston Holmes, Jennifer Saultz, Ayad Hamdan, Anne Robinson, Mili Mandal, Aakash Patel, Thorsten Graef, Anita Seto, Umar Farooq; Fox Chase Cancer Center, O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Norton Cancer Institute, Texas Oncology PA, OHSU – Oregon Health and Science University, University of California San Diego Medical Center, Artiva Biotherapeutics Inc., University of Iowa Hospitals and Clinics; Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia, Hematologic Malignancies, Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL; Clinical Trial Registration Number, NCT04673617, Abstract #7529, Poster Board #80, Hall A, June 5, 2023, 8:00 AM CDT.
Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study. Namrata Vijayvergia,* Elizabeth Handorf, Pamela Kunz, Emel Alkim, Lauren Burke, Paul Catalano, Noah Graham, Laura Levin, Weier Li, Caitlin Meeker, Daniel Rubin, Anush Narasimhan Sridharan, Peter O’Dwyer, Terence Wong, Jordan Anaokar; Fox Chase Cancer Center, Temple University Health System, Yale Cancer Center, Stanford University, University of North Carolina at Chapel Hill, Dana-Farber Cancer Institute, Fox Chase Cancer Center, University of Pennsylvania Department of Medicine, Duke Cancer Institute; Session Type: Poster Session; Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Abstract #4133, Poster Board #454, Hall A, June 5, 2023, 8:00 AM CDT.